2-Phenylindol-3-yl-acetamid | 4567-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Phenylindol-3-yl-acetamid
• 英文别名: 2-(2-phenyl-indol-3-yl)-acetamide；2-Phenylindole-3-acetamide；2-(2-phenyl-1H-indol-3-yl)acetamide
• CAS: 4567-07-1
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: QKFJFDRDAWQCEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
  申请人：Bornhop J. Darryl

  公开号：US20060147379A1

  公开（公告）日：2006-07-06

  Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.

  与近红外分子成像、体外和体内功能成像、治疗/疗效监测以及癌症和转移活动成像相关的化合物和方法。所展示的化合物和方法涉及外周苯二氮卓类受体成像领域、代谢成像、细胞呼吸成像、作为靶向药物的细胞增殖成像，这些药物包含信号代理。
• Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
  申请人：Drug Innovation & Design, Inc.

  公开号：US20030138432A1

  公开（公告）日：2003-07-24

  The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

  本发明涉及一种新的选择性细胞靶向的组合物、方法和应用。本发明的目的是为了实现对目标细胞的选择性输送和/或选择性激活效应分子，以进行诊断或治疗。本发明涉及多功能前药或靶向载体，其中每个功能都能增强靶向选择性、亲和力、细胞内转运、激活或解毒。本发明还涉及超低剂量、多靶点、多药物化疗和靶向免疫疗法，用于癌症治疗。
• Multi-use multimodal imaging chelates
  申请人：——

  公开号：US20030129579A1

  公开（公告）日：2003-07-10

  Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based chelates to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.

  基于环状四胺（“cyclen”）形成的聚合物配位剂可用作多模成像组织细胞的对比剂。这些基于cyclen的配位剂通常是由具有不同配位离子、磷酸酯链和光收集基团的聚合物分子形成的。通过改变配位离子、磷酸酯链长度和/或光收集基团，可以使用不同的成像技术，如MRI、CT、荧光和吸收、X射线和NIR等来成像组织细胞。此外，这些基于cyclen的配位剂可以被结合以提供针对所需组织细胞的特定部位递送。这些基于cyclen的配位剂也可以通过将其附着到聚合物递送载体上来递送到组织细胞。尽管这些基于cyclen的配位剂具有广泛的应用，但首选用于癌细胞的成像，如脑癌，以改善癌组织的切除。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING
  申请人：Bornhop J. Darryl

  公开号：US20080031823A1

  公开（公告）日：2008-02-07

  Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.

  与近红外分子成像、体外和体内功能成像、治疗/疗效监测以及癌症和转移活动成像相关的化合物和方法。展示的化合物和方法涉及外周苯二氮平受体成像、代谢成像、细胞呼吸成像、细胞增殖成像作为包含信号剂的靶向剂。